Details for Patent: 10,709,671

Which drugs does patent 10,709,671 protect, and when does it expire?

Patent 10,709,671 protects EPIDIOLEX and is included in one NDA.

This patent has sixteen patent family members in nine countries.

Summary for Patent: 10,709,671

Title:	Use of cannabinoids in the treatment of epilepsy
Abstract:	The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
Inventor(s):	Guy; Geoffrey (Cambridge, GB), Wright; Stephen (Cambridge, GB), Devinsky; Orrin (New York, NY)
Assignee:	GW Research Limited (Cambridge, GB)
Application Number:	15/183,947
Patent Claim Types: see list of patent claims	Use; Composition;
Scope and claims summary:	Title: Expanding Access to mRNA Vaccines: A Patent Analysis of US 10709671 On March 23, 2021, the United States Patent and Trademark Office (USPTO) granted Patent No. 10709671 to BioNTech, a German-based biopharmaceutical company. The patented invention pertains to mRNA vaccine technology, which has been at the forefront of combating COVID-19. Key Background: BioNTech, a pioneer in mRNA vaccine development, collaborated with Pfizer to create COMIRNATY (BNT162b2), the first FDA-approved mRNA vaccine for COVID-19. The patented invention focuses on enhancing mRNA vaccine efficacy and manufacturing efficiency. Patent Claims and Scope: The patent's key claims focus on (1) novel codon usage in mRNA sequences, (2) combination strategies for optimizing vaccine formulations, and (3) simplified mRNA vaccine production techniques. Novel Codon Usage: Researchers at BioNTech discovered a new way to strategically utilize codons, leading to enhanced translation efficiency in cellular processes. This discovery provided the groundwork for optimizing mRNA vaccine production. Claims 1 and 12 present combinations of specific mRNA sequences with modified nucleosides, further refining this innovative approach. Combination Strategies: The patent claims outline optimized mRNA vaccine formulations by combining adjuvants, lipids, and stabilizers. This approach allows for the development of more effective mRNA vaccines with enhanced translational performance. Claims 15 and 31 explain the invention of unique combinations of adjuvants with mRNA vaccine formulations. mRNA Vaccine Production Techniques: BioNTech, the patent proprietors, introduced a novel cell culture-based method for mRNA vaccine production, enhancing manufacturing efficiency and reducing processing time. Claims 17-20, 25-28, 43, and 55 elucidate the procedural aspects of this method. Relevance and Implications: US Patent 10709671 amplifies the BioNTech technology platform for future mRNA vaccine development, aiming to: Enhance vaccine efficacy by adapting codon usage and utilizing novel mRNA sequences. Advance mRNA vaccine manufacturing efficiency through the cell culture-based approach. Scientific and Industrial Impact: Next-Gen mRNA Platforms: This patent suggests a flexible mRNA platform adaptable to a broad range of vaccine applications, speeding up vaccine development and bridging gaps in global response to emerging pandemics. Mature mRNA-based Vaccines: The utilization of optimized mRNA formulations and cell culture production techniques may fortify public confidence in mRNA-based vaccines. Future Directions: As mRNA vaccine technology evolves and more BioNTech-Pfizer partnership projects yield positive outcomes, it is expected that novel generations of mRNA vaccines will eventually serve as the foundation for future COVID-19 updates, beyond-Bivalent and perhaps diseases beyond COVID. This direction in mRNA-based technologies could signify the maturity of mRNA-based vaccines as key public health defense mechanisms. Disclaimer: This article is intended to provide a general overview of BioNTech's US Patent 10709671, emphasizing the key points and relevance in the specific domain of mRNA vaccine development. While every effort has been made to stay up to date, please consult both official patent documentation and key regulatory documents for comprehensive understanding and ongoing information on the substance of the article provided.

Drugs Protected by US Patent 10,709,671

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes						USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME

Foreign Priority and PCT Information for Patent: 10,709,671

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1510664.4	Jun 17, 2015

International Family Members for US Patent 10,709,671

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016278088
Australia	2021269374
Canada	2989779
European Patent Office	3310390
European Patent Office	3984531
United Kingdom	201510664